Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals, Inc., a biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant infections, has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its AP-SA02 product. This designation is based on compelling Phase 2 clinical data showing that AP-SA02 may offer substantial improvement over existing treatments for complicated Staphylococcus aureus bacteremia (SAB), including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA).

The Breakthrough Therapy designation is intended to expedite the review process for medicines that treat serious or life-threatening conditions and have preliminary evidence of potential substantial improvement over available therapies. AP-SA02 now holds this designation, along with Qualified Infectious Disease Product (QIDP) and Fast Track designations, providing strong regulatory validation for the company’s innovative treatment.

According to Dr. Deborah Birx, Chief Executive Officer of Armata, the designation underscores the urgent need for new treatment options for patients with complicated SAB.

The diSArm study, a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study, demonstrated the safety and efficacy of AP-SA02. The study involved adults with complicated SAB and utilized Armata's proprietary purification process to produce a high-purity, high-titer AP-SA02 drug product formulation. This formulation allowed for repetitive dose intravenous administration every six hours for five days. The dosing regimen was well tolerated, with no serious adverse events attributed to AP-SA02. When added to best available antibiotic therapy (BAT), AP-SA02 demonstrated higher and earlier clinical cure rates than placebo plus BAT.

At the end-of-study assessment, 28 days after completion of BAT, 100% of patients treated with AP-SA02 maintained clinical response without relapse, compared with 75% of patients receiving placebo. Patients treated with AP-SA02 also showed favorable trends across multiple measures of disease resolution, including more rapid normalization of C-reactive protein (CRP) and Interleukin-10 (IL-10), biomarkers associated with mortality risk and complications in SAB.

The Breakthrough Therapy designation is supported by these data and reflects the FDA's enhanced engagement with Armata. The company is committed to working closely with the Agency to efficiently advance the development and review of AP-SA02, with the goal of bringing this potential new treatment option to patients as quickly as possible.

The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, which is anticipated to initiate in the second half of 2026. This study will further validate the efficacy and safety of AP-SA02 in a larger patient population, potentially leading to its approval as the first antibacterial therapy based on superiority to current standard-of-care treatment in this patient population.

The Breakthrough Therapy designation, combined with the QIDP and Fast Track designations, positions AP-SA02 as a promising candidate for the treatment of complicated SAB. Armata's commitment to developing innovative bacteriophage therapeutics for antibiotic-resistant infections continues to be a focus, with the potential to significantly improve patient outcomes in this challenging clinical setting.